DGLY Archives - Page 4 of 4 - Blue Horseshoe Stocks

Blue Horseshoe Stocks: Bottom Bounceplay & More

Lucas Energy, Inc. LEI

We’re looking at LEI this morning as a possible bottom bounce play. The stock has been under general consolidation for the past couple of months, and is getting to a point where we want to begin monitoring for a recovery.

A glance at the chart below shows a few indicators ready to go bullish, and a stock that is trading very close to its 52-week lows. As you know, we’re always interested in stocks near their annual low points; the strategy has worked for us on countless occasions.

It appears LEI has a bit of resistance to contend with in the channel between .55 (July support level) and the 50DMA of .57, but beyond that, there isn’t a whole lot in the way of this thing testing previous highs in the .65-.70 range.

Get More Info on LEI @ www.lucasenergy.com

Petroleo Brasiliero S.A. (Petrobras) PBR – Options Update

Our continual coverage of the PBR options chain has still yet to fail; if you recall, we were speculating on the 08/22 $15.50 and $16 Calls beginning on Friday, with the intent to execute a possible swing trade into this week. A move up that has PBR headed toward annual highs has facilitated quite the opportunity for us.

Those who were following along with our idea could have gotten in those $16’s at a low of .44 on Friday, and as of yesterday’s high of 1.28, the value of those contracts showed an overall increase of 190% Not bad at all for a span of only three sessions.

We also observed some abnormally high volume in the January $19 Calls as they traded over 48K contracts. We’ll want to radar these Calls as well.

For another potential short-term play, we’ll also have an eye on the $16.50 and $17.00 Weekly Calls.

Extended Watchlist:
FOLD, DGLY, NQ, HPJ

Blue Horseshoe Stocks: The Week in Review

Looking Back on a Stellar Week

We couldn’t have asked for a better week of winning picks, especially coming off of a holiday weekend, so to wrap things up we’re going to go over all of our successful picks, and what kinds of moves they made.

GEI Global Energy Corp. GEIG

Of course the big winner for this week was GEIG, and in fact was one of our most successful picks in quite some time. We initiated coverage of GEIG on Wednesday, the stock opened up and saw a low of .0098 very briefly before exploding to a high of .08, a single-session move of 716% While it’s unlikely that traders could have picked up any of those sub-penny shares, the real action began around .015, still leaving the opportunity at a high number, with gains of up to 433% being very possible. The stock traded record volume.

Camtek, Ltd. CAMT

CAMT came off of Monday’s extended watchlist to perform exceptionally well for us, running from a low of 3.42 to 5.14, a solid 50% gainer on more than 40x its 3-month average volume.

GW Pharmaceuticals, Inc. GWPH

On Tuesday, we were talking about GWPH, stating: “Once we see a solid level of support established and GWPH begins to rebound, then we’ll be able to adjust our options-trading strategies accordingly.” Sure enough, the stock did indeed find solid support at 85.32. We would subsequently see an uptrend carry GWPH as high as 93.97. As a result, the $85 Weekly Calls traded in an impressive range from 4.30 to 9.60, a total possible gain of 123% while the $90 Calls made an even more impressive move. They would run from 1.55-5.69, giving traders a chance at profits up to 267% We’ll continue to watch those weekly contracts today for a possible intraday flip opportunity.

American Apparel, Inc. APP

This spring, we started reminding people that as the retail season approaches, APP is a stock that we traditionally play for nice gains every year. 2014 has proven no different. We saw a low of .51
out of APP on June 24th, and the stock has made more than a 100% move up, touching 1.05 during yesterday’s session. The retail season has yet to even kick into gear, and already we’ve been able to reap some excellent rewards from this retail stock; it will certainly remain on our watchlist as the summer begins to wind down.

Inception Mining, Inc. IMII

We first added IMII to our lists yesterday as a long term-mining play. We wanted the stock to hold support off of the 200DMA, and break resistance at the 50DMA, and that’s just what we got. The stock has made higher lows and higher highs over the past couple of sessions, so it appears we’re off to a great start with this one. On the chart, the RSI cracked above the 50-line, and the MACD is still heading for a bullish cross, so we’re still very interested to see what this play could do in the days and weeks ahead.

Extended Watchlist:
HALO, DGLY, JOEZ, EVRY, PBR

CNAT, GOGO, UNIS, CAMT & Extended Watchlist

Conatus Pharmaceuticals, Inc. CNAT

We caught CNAT on our scanner this morning, and is definitely a stock we’d like to keep an eye on today, following an FDA-related announcement regarding a drug that the company has under development receiving “Orphan Drug” status. FDA plays have provided us with countless opportunities in the past, especially when the news is untraded upon, so we’ll be interested to see how well CNAT fares today as a result.

SAN DIEGO, Dec. 2, 2013 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (CNAT), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Conatus’ drug candidate emricasan for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The FDA’s Orphan Drug Designation program is intended to encourage the development of drugs and biologics that may provide benefit to patients suffering from rare diseases or conditions.

Conatus is developing emricasan, a first-in-class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death (or apoptosis), for the treatment of patients with chronic liver disease and significant unmet medical need.

GOGO, Inc. GOGO

We have been hot on the trail of GOGO since our first mention on Monday Sept. 16th when it was trading as low as 14.79. We witnessed the stock’s 52-wk high a few weeks later on Nov. 14th (31.55), and then it consolidated to find support at 24.24.

Yesterday, GOGO re-established its 52-wk high at 31.65, and appears to want to gap up and continue its run today. This morning, the company has news out concerning the green light is has received to install its wifi satellite technology on Boeing 747 aircraft. and we’ve seen pre-market trades going off as high as 32.75. From our original alert price, that marks registers as a 121% gain. Heading into today’s session, we’d like to see the previous 52-wk high of 31.55 hold as support on any future pullbacks.

ITASCA, Ill., Dec. 2, 2013 /PRNewswire via COMTEX/ — Gogo (NASDAQ: GOGO), the world leader of in-flight connectivity and a pioneer in wireless in-flight digital entertainment solutions, passed a key milestone in launching its international connectivity service by receiving an STC to install its Ku-satellite technology on Boeing 747-400 aircraft.

Gogo will begin testing the new service immediately and plans to offer the service for customer usage by the first quarter of 2014. The technology will give travelers and crew access to the Internet. The service will also offer passengers Gogo Vision, Gogo’s wireless in-flight entertainment service.

Unilife Corp. UNIS

UNI hits our radar screens as another play with fresh news and a chart that is gapping up premarket. UNIS has a potentially lucrative arrangement in the works with European Pharma giant, Novartis.

YORK, Pa., Dec. 2, 2013 /PRNewswire/ — Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS, ASX: UNS) today announced an agreement with Novartis to supply clinical products from one of its platforms of injectable drug delivery systems for use with one of Novartis’ targeted early-stage pipeline drugs.

Under this agreement, Unilife will supply Novartis with a customized delivery device, consisting of syringe, needle, tubing, controller and pump, to enable administration of a novel investigational Novartis drug into a targeted organ in clinical trials. Unilife has granted Novartis an option for exclusivity under this agreement.

Camtek, Ltd. CAMT

Yesterday wasn’t the first time we’ve mentioned CAMT on our extended watchlist only to see the stock turn in an impressive performance; last Monday, we tagged CAMT as a possible runner, and subsequently witnessed a pop from 4.11-5.29 (+29%). In a repeat of that scenario, yesterday we saw the stock trade from a low of 4.20 on up to 5.75, for a possible gain of 37%

Cheers to anyone who was able to take advantage of those very timely alerts!

Extended Watchlist:
IACH, OMED, ETRM, FRO, DGLY, NAVB